166959-29-1Relevant academic research and scientific papers
A high dielectric constant non-fullerene acceptor for efficient bulk-heterojunction organic solar cells
Liu, Xi,Xie, Boming,Duan, Chunhui,Wang, Zhaojing,Fan, Baobing,Zhang, Kai,Lin, Baojun,Colberts, Fallon J.M.,Ma, Wei,Janssen, René A.J.,Huang, Fei,Cao, Yong
supporting information, p. 395 - 403 (2018/01/12)
The majority of organic semiconductors have a low relative dielectric constant (?r r > 6) has attracted a very limited attention. Moreover, high performance OSCs based on high dielectric constant photovoltaic materials are still in their infancy. Herein, we report an oligoethylene oxide side chain-containing non-fullerene acceptor (ITIC-OE) with a high relative dielectric constant of ?r ≈ 9.4, which is two times larger than that of its alkyl chain-containing counterpart ITIC. Encouragingly, the OSCs based on ITIC-OE show a high power conversion efficiency of 8.5%, which is the highest value for OSCs that employ high dielectric constant materials. Nevertheless, this value is lower than those of ITIC-based control devices. The less phase-separated morphology in blend films due to the reduced crystallinity of ITIC-OE and the too good miscibility between PBDB-T and ITIC-OE are responsible for the lower device performance. This work suggests additional prerequisites to make high dielectric constants play a significant role in OSCs.
GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
-
Page/Page column 248, (2014/04/03)
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
-
Page/Page column 13, (2008/06/13)
Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
Heterocyclic derivatives
-
, (2008/06/13)
Compounds of formula (I) wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 are joined together so that CR1 14 CR2 is a double bond; X is selected from --Ch2 CH
Novel Water-Soluble Organosilane Compounds as a Radical Reducing Agent in Aqueous Media
Yamazaki, Osamu,Togo, Hideo,Nogami, Genki,Yokoyama, Masataka
, p. 2519 - 2523 (2007/10/03)
The development of novel water-soluble organosilane compounds and their application to radical reactions in water medium have been studied. A series of novel organosilane compounds having hydrophilic groups, such as an ether group and a hydroxy group in the side chain to bear hydrophilicity, were synthesized by the reaction of trichlorosilane or tetrachlorosilane and Grignard reagents. The reactivities of these organosilane compounds were studied in the radical reduction of 2-bromoethyl phenyl ether in ethanol in the presence of triethylborane under aerobic conditions. The results showed that diarylsilane was the most effective among them. The radical reduction of alkyl and aryl halides with diarylsilane was applied to a reaction in aqueous media, which gave the corresponding reduction product in good yields. Thus, the present organosilanes are very useful for the reduction of water-soluble substrates, such as halo sugars in water.
